Loss of p16INK4A expression in low-grade ovarian serous carcinomas

International Journal of Gynecological Pathology

Volumn 30, Issue 1, 2011, Pages 22-29

  Schlosshauer, Peter W ^a   Deligdisch, Liane ^a   Penault Llorca, Frédérique ^b   Fatemi, Delaram ^a   Qiao, Rui ^a   Yao, Shen ^a   Pearl, Meghan ^a   Yang, Zhen ^c   Sheng, Tao ^c   Dong, Jianli ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRE JEAN PERRIN   (France)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR SUPPRESSOR PROTEIN; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; CANCER STAGING; CYSTADENOCARCINOMA; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 78650930797     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181ed89b3     Document Type: Article

References (32)

1. Vang R, Shih I, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16:267-82.
2. Kobel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 2008;10:e22.
3. Ho CL, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8.
4. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-9.
5. Shih I, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11:7273-9.
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
7. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160: 1223-8.
8. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-24.
9. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008;65:3525-44.
10. Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:1169-82.
11. Rotolo S, Diotti R, Gordon RE, et al. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int J Cancer 2005;115:164-9.
12. Sato Y, Sugie R, Tsuchiya B, et al. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol 2001;10:265-71.
13. Shackelford W, Deng S, Murayama K, et al. A new technology for mutation detection. Ann N Y Acad Sci 2004;1022:257-62
14. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-5.
15. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. computer-assisted image analysis (QIC score) versus subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
16. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007;31:1007-12.
17. Quddus MR, Rashid LB, Hansen K, et al. High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman. Histopathology 2009;54:771-3.
18. Jeyapalan JC, Sedivy JM. Cellular senescence and organismal aging. Mech Ageing Dev 2008;129:467-74.
19. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005;24:363-8.
20. ONeill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-9.
21. Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol 2009;28:179-86.
22. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600- associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
23. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21: 27-38.
24. Zhao Y, Zhang Y, Yang Z, et al. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun 2008;370:509-13.
25. Fujita M, Enomoto T, Haba T, et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 1997; 74:148-55.
26. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
27. Havrilesky LJ, Alvarez AA, Whitaker RS, et al. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 2001;83:491-500.
28. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
29. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004;202:336-40.
30. Ueda M, Toji E, Noda S. Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int J Gynecol Cancer 2007;17:794-7.
31. Verbruggen MB, Sieben NL, Roemen GM, et al. v-raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. Int J Gynecol Cancer 2009;19:1560-3.
32. Hsu CY, Bristow R, Cha MS, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004;10:6432-6.